The investigation of the tolerability and the cost, due to the drug change to novel oral anticoagurants (rivaroxaban) from warfarin in patients with nonvalvular atrial fibrillation in the perioperative period
Not Applicable
- Conditions
- onvalvular Atrial Fibrillation
- Registration Number
- JPRN-UMIN000011103
- Lead Sponsor
- Osaka General Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1)The patients with contraindication of Xarelto 2)The patients who are not allowed to participate in the trial by the principal investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1)Inpatient days 2)In-hospital medical expense (including outpatient therapy)
- Secondary Outcome Measures
Name Time Method Tolerability (existence or nonexistence of hemorrhage and orischemic events)